Summary: A pilot study reveals that small doses of ketamine may help reduce or eliminate withdrawal symptoms for patients transitioning from fentanyl addiction to buprenorphine treatment, potentially offering a new approach to opioid addiction treatment.
Estimated reading time: 6 minutes
A pilot study led by researchers at the University of Washington School of Medicine has uncovered a potential new tool in the fight against opioid addiction. The research, published in Addiction Science & Clinical Practice, suggests that ultra-low doses of ketamine could significantly ease the withdrawal symptoms that often prevent individuals from starting potentially life-saving addiction treatments.
In the United States, where drug overdose is the leading cause of injury deaths among young adults, this finding could have far-reaching implications. With fentanyl alone responsible for over 70,000 deaths annually, any advancement in addiction treatment could save thousands of lives.
Breaking the Cycle of Addiction
For many individuals trapped in the grip of fentanyl addiction, the fear of withdrawal symptoms creates a seemingly insurmountable barrier to recovery. These symptoms, which include muscle cramps, nausea, chills, sweats, and intense cravings, often deter users from initiating treatment with methadone or buprenorphine – medications that can dramatically reduce the risk of overdose death.
Dr. Lucinda Grande, clinical assistant professor of family medicine at the University of Washington School of Medicine and lead author of the study, explains the significance of their findings: “The main takeaway is that we have found an easier way for people trapped in the grip of fentanyl addiction to get started in treatment.”
Ketamine: A Bridge to Treatment
The study, conducted over 14 months, involved prescribing ketamine to 37 fentanyl-addicted patients who were hesitant to try buprenorphine due to fear of withdrawal symptoms. Of the 24 patients who actually tried the drug, 16 successfully completed the transition to buprenorphine treatment.
Dr. Tom Hutch, medical director of the opioid treatment program at We Care Daily Clinics in Auburn, Washington, and co-author of the study, highlighted the unique role of ketamine in this context: “Ketamine, at an imperceptibly low dose, helps bridge that gap” between addiction and treatment initiation.
The researchers used a remarkably small dose of ketamine – just 16 mg administered sublingually as a lozenge or syrup. This dosage is a fraction of what’s typically used for anesthesia and less than half of the smallest dose prescribed for depression treatment.
Promising Results
The study’s results are encouraging:
- Most patients reported a reduction or elimination of withdrawal symptoms after each ketamine dose.
- The effects of ketamine lasted for hours.
- Of the last 12 patients who completed the transition to buprenorphine, 92% remained in treatment for at least 30 days.
These outcomes suggest that ultra-low-dose ketamine could be a valuable tool in helping individuals overcome the initial hurdles of addiction treatment.
Questions and Considerations
While the results of this pilot study are promising, several questions remain:
- How will these findings translate to larger, more diverse patient populations?
- What are the long-term effects of using ultra-low-dose ketamine in this context?
- How might this approach be integrated into existing addiction treatment programs?
Dr. Grande expressed hope that these results will be confirmed by larger studies, stating, “I am excited about these results. This is a wonderful opportunity to save lives.”
It’s important to note that this research is still in its early stages. The study’s small sample size and lack of a control group mean that more extensive research is needed to fully understand the potential of this approach.
As the opioid crisis continues to claim lives across the United States, innovative approaches like this one offer a glimmer of hope. By potentially lowering the barrier to treatment initiation, ultra-low-dose ketamine could help more individuals take the first step towards recovery from opioid addiction.
Quiz
- What was the main purpose of using ketamine in this study?
- How many patients were initially prescribed ketamine in the study?
- What percentage of patients who completed the transition to buprenorphine remained in treatment for at least 30 days?
Answer Key:
- To reduce or eliminate withdrawal symptoms for patients transitioning from fentanyl addiction to buprenorphine treatment.
- 37 patients
- 92% of the last 12 patients who completed the transition
Further Reading:
- National Institute on Drug Abuse – Opioid Overdose Crisis
- Substance Abuse and Mental Health Services Administration – Buprenorphine
- FDA – Information about Medication-Assisted Treatment (MAT)
Glossary of Terms:
- Buprenorphine: A medication used to treat opioid addiction by reducing cravings and withdrawal symptoms.
- Ketamine: A medication primarily used for starting and maintaining anesthesia, but also used in lower doses to treat depression and, as this study suggests, potentially opioid withdrawal symptoms.
- Fentanyl: A powerful synthetic opioid that is similar to morphine but 50 to 100 times more potent.
- Opioid withdrawal: The group of symptoms that occur upon the abrupt discontinuation or decrease in intake of opioid drugs.
- Sublingual: A route of administration for certain medications where the substance is placed under the tongue to be absorbed into the blood through the tissues.
- Pilot study: A small-scale preliminary study conducted to evaluate feasibility, time, cost, adverse events, and improve upon the study design prior to performance of a full-scale research project.
Enjoy this story? Get our newsletter! https://scienceblog.substack.com/
